4th Asia-Pacific Conference Preliminary Program - Monday, 6 September 2010
 
Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
Monday, 6 September 2010
Sunday, 5 September >> Monday, 6 September >> Tuesday, 7 September
7:00AM 8:15AM
ISPOR ASIA CONSORTIUM MEETINGS (BY INVITATION)
Health Technology Producers (Industry) Committee Business Meeting
Health Service Providers (Clinicians) Committee Business Meeting
Health Technology Assessment Agencies (HTA) Committee and Health Care Policymakers & Payers (Policymakers & Payers) Committee Joint Business Meeting
8:30AM 9:10AM
WELCOME
Simultaneous Thai/English translation provided
Thai, Korean & Chinese presentations translated to English; English presentations translated to Thai, Korean & Chinese
Surachat Ngorsuraches PhD, RPh, Conference Co-chair, and Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand
Vithaya Kulsomboon PhD, Conference Co-chair, Associate Professor and Associate Dean for Planning and Development, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Scott D. Ramsey MD, PhD, 2010-2011 ISPOR President,  Member, Fred Hutchinson Cancer Research Center, and Professor, Department of Medicine, University of Washington, Seattle, WA, USA
Bong-Min Yang PhD, 2010-2012 Chair, ISPOR Asia Consortium Executive Committee, and Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea
Boonsom Siribumrungsukha PhD Boonsom Siribumrungsukha PhD, President, Prince of Songkla University, Songkhla, Thailand
Punsiri  Kullanartsiri PhD
Her Excellency Deputy Minister of Public Health, Bangkok, Thailand
9:10AM 9:30AM
MINISTRY OF PUBLIC HEALTH PRESENTATION
Simultaneous Thai/English translation provided
Thai presentation translated to English
 
   
Future Thai Pharmaceutical Economics and Policy

Yupin Lawanprasert PhD
Senior Advisor in Safety and Effectiveness and Advisory in Safety and Efficacy of Health Products, Food and Drug Administration, Ministry of Public Health, Bangkok, Thailand

 
9:30AM 11:00AM
FIRST PLENARY SESSION
Simultaneous Thai/English translation provided
Thai, Korean & Chinese presentations translated to English; English presentations translated to Thai, Korean & Chinese
HEALTH CARE REIMBURSEMENT DECISION-MAKING IN ASIA: POLICYMAKER PERSPECTIVES

This session focuses specifically on the following points: 1) current practices in Asia; 2) benefits and barriers of using HTA and pharmacoeconomics; 3) availability of necessary and relevant information; and 4) major difficulties faced as a result of current practices. Policymakers from Thailand, China Mainland, South Korea, and Taiwan will share their insights in health care reimbursement decision-making.

Moderator:
Moderator: Vithaya Kulsomboon PhD Vithaya Kulsomboon PhD, Associate Professor and Associate Dean for Planning and Development, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Panelists:
Ammar Siamwalla PhD Ammar Siamwalla PhD, Distinguished Scholar, Thailand Development Research Institute, Bangkok, Thailand
Wei Meng PhD Wei Meng MA , Deputy Director, Health Insurance Department, Ministry of Human Resource and Social Security, Beijing, China
Bo-Yeon Kim RPh, MPH, Executive Director, Health Insurance Review and Assessment Service (HIRA), Seoul, South Korea
heng-Hua Lee PhD Cheng-Hua Lee PhD, Deputy Director General, Bureau of National Health Insurance, Department of Health, Taipei, Taiwan
11:00AM 11:30AM
BREAK, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING
11:30AM 12:30PM
ISSUE PANELS & WORKSHOPS SESSION I
English presentations translated to Thai, Korean & Chinese

IP1: ISSUES IN DEVELOPING PHARMACOECONOMIC GUIDELINES IN ASIA

Moderator: Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Panelists: Gordon G. Liu PhD, Professor of Economics, The Health Economics and Management Institute, Guanghua School of Management, Peking University, Beijing, China; Isao Kamae MD, DrPH, Professor of Pharmacoeconomics, JPMA Research and Education Project, Keio University, Graduate School of Health Management, Fujisawa-City, Kanagawa, Japan; Bong-Min Yang PhD, Professor, School of Public Health, Seoul National University, Seoul, South Korea

 

IP2: HEALTH ECONOMIC CONSIDERATIONS FOR PERSONALIZED MEDICINE IN ASIA: USING GENOMIC PROFILING TO GUIDE TREATMENT DECISIONS IN EARLY STAGE BREAST CANCER

Moderator: Calvin Chao MD, MBA, Director of Medical Affairs, Medical Affairs, Genomic Health, Inc., Redwood City, CA, USA
Panelists: Gilberto de Lima Lopes MD, MBA, Assistant Director for Clinical Research, Johns Hopkins Singapore International Medical Centre, John Hopkins University, Singapore, Singapore; Beth O'Leary MPH, Senior Director, Health Economics, Covance, North Ryde, NSW, Australia

 

W1: ADVANTAGES AND DISADVANTAGES OF THE MIXED TREATMENT COMPARISONS FOR HEALTH TECHNOLOGY ASSESSMENT

Discussion Leaders: Jeonghoon Ahn PhD, MA, Senior Director, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea; SungJu Kim PhD Student, Health Economics Project Manager, Market Access, Novartis Korea, Seoul, South Korea

 

W2: MEASUREMENT STRATEGIES FOR PRODUCTIVITY LOSS IN ECONOMIC EVALUATIONS

Discussion Leaders: Bruce Crawford MA, MPH, General Manager, Asia, Mapi Values, Tokyo, Japan; Somali Misra Burgess PhD, Director, Global Health Outcomes Strategy & Research, Allergan, Inc, Irvine, CA, USA; Christopher Evans PhD, MPH, Development Director - US, Mapi Values, Boston, MA, USA

 

W3: APPLICATION OF BUDGET IMPACT ANALYSIS IN THE DEVELOPMENT OF HEALTH CARE REIMBURSEMENT POLICY IN ASIA-PACIFIC

Discussion Leaders: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China; Raoh-Fang Pwu PhD, Acting Director, Center for Drug Evaluation, Division of Health Technology Assessment, Taipei, Taiwan; Yabing Zhang MSc, MEd, PhD, Director of Health Policy Research Department, Health Development Research Center, Shanghai Municipal Health Bureau, Shanghai, China; Mingliang Zhang PhD, MBA, Senior Director, Health Economics and Pricing, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA

12:30PM – 3:15PM
LUNCH, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING
12:45PM 1:45PM
EDUCATIONAL SYMPOSIUM (Sponsored by Eli Lilly)
Simultaneous Thai/English translation provided
English presentations translated to Thai, Korean & Chinese
HTA Challenges in Asia: Progress Through Partnerships
1:00PM 2:20PM
ISPOR ASIA CONSORTIUM MEETING (BY INVITATION)
Publication Committee Business Meeting
2:00PM – 3:00PM
EDUCATIONAL SYMPOSIUM (Sponsored by IMS Health)
Opportunity and Challenges In The Emerging Markets of Asia: Implications for Pricing, Market Access and Health Economics and Outcomes Research
3:15PM 4:30PM
SECOND PLENARY SESSION
Simultaneous Thai/English translation provided
Thai & Chinese presentations translated to English; English presentations translated to Thai, Korean & Chinese
National Drug Policies to Local Formulary Decisions in ASIA-PACIFIC: Drug Listing Challenges and Opportunities

In this session, speakers from selected countries will share their experiences and lessons learned in translating national drug policies to local formulary decisions. Criteria for drug listing at the national, provincial, and institutional levels in Thailand, China, and Australia will be discussed. Examples of new drugs recently listed in these countries and the use of pharmacoeconomics and outcomes research in this process will be highlighted.

Moderator:
Moderator: Shanlian Hu MD, MS Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China
Panelists:
Suwit Wibulpolprasert MD Suwit Wibulpolprasert MD, Senior Advisor on Disease Control, Ministry of Public Health, Nonthaburi, Thailand
Huexui Han PhD Huexui Han PhD, Deputy Chief, Department of Drug Policy and Essential Medicines, Ministry of Health, Beijing, China
Paul Scuffham PhD, PGDip (Arts) Paul Scuffham PhD, PGDip (Arts), Professor and Chair in Health Economics, School of Medicine, Griffith University, Meadowbrook, QLD, Australia
Respondents:
Sheldon Kong PhD Sheldon Kong PhD, Head, Global Outcomes Research, Merck & Company, Inc., Whitehouse Station, NJ, USA
Hong Li PhD, MPH Hong Li PhD, MPH, Group Director, Global Health Economics and Outcomes Research, Asia Pacific, Bristol-Myers Squibb Company, Wallingford, CT, USA
4:30PM – 4:45PM
BREAK, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING
4:45PM 5:45PM
RESEARCH PODIUM PRESENTATIONS SESSION I

COST-EFFECTIVENESS STUDIES

CE1

COST-EFFECTIVENESS ANALYSIS OF GLUCOSAMINE SULPHATE FOR THE TREATMENT OF OSTEOARTHRITIS IN THAILAND

 

Chaiyakunapruk N1, Saokaew S2, Pansang S3
1Center of Pharmaceutical Outcomes Research (CPOR), Phitsanulok, Thailand, 2Naresuan University Phayao, Muang, Phayao, Thailand, 3Naresuan University, Muang, Phitsanulok, Thailand

   

CE2

LIFETIME CLINICAL PROJECTIONS FOR OVERWEIGHT OR OBESE SUBJECTS WITH IMPAIRED GLUCOSE INTOLERANCE BASED ON THE LONG TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND DIABETES PREVENTION PROGRAM OUTCOMES STUDY

 

Palmer AJ, Tucker DM
Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia

   

CE3

COST-UTILITY ANALYSIS OF CHOLINESTERASE INHIBITORS IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE

 

Turongkaravee S
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

   

CE4

ECONOMIC EVALUATION OF REHABILITATION SERVICES FOR INPATIENT WITH STROKE IN TWO REGIONAL HOSPITALS IN THAI CONTEXT

 

Khiaocharoen O1, Teerawattananon Y2, Pannarunothai S3, Riewpaiboon W4
1Naresuan University Faculty of Medicine, Pitsanuloke, Thailand, 2The Health Intervention and Technology Assessment Program (HITAP), Nontthaburi , Thailand, 3Centre for Health Equity Monitoring, Phitsanulok, Thailand, 4The Program of Health Promotion for People with Disabilities in Thai Society, Nonthaburi, Thailand

   
CANCER STUDIES

CN1

CERVICAL CANCER SCREENING PROGRAMME IN THAILAND: ASSESSMENT OF SERVICE COVERAGE AND DETERMINANTS OF PROGRAMME UPTAKE

 

Sirisamutr T, Butchon R, Putchong C, Praditsitthikorn N, Insrisawang L, Suksomboon N, Tantivess S, Teerawattnanon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand

   

CN2

A SYSTEMATIC REVIEW AND META-ANALYSIS OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER

 

Lerdkiattikorn P1, Chaikledkaew U1, Kingkaew P2, Teerawattananon Y2
1Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand, 2Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand

   

CN3

QUALITY OF LIFE IN ADVANCED CANCER PATIENT – COMPARISON OF PATIENT REPORTED OUTCOME(PRO) AND PROXIES ASSESSMENT

 

Choi J1, Miyashita M2, Kim B3
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Tohoku University School of Health Sciences, Sendai, Japan, 3Hanyang University, Seoul, South Korea

   

CN4

CAN WE CORRECTLY TARGET HIGH COST THERAPIES? THE DIAGNOSTIC ACCURACY OF HISTOLOGY IN DIFFERENTIATING BETWEEN SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

 

Paech D, Weston A
Health Technology Analysts Pty Ltd, Sydney, New South Wales, Australia

 
HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

EARLY ALERT SYSTEMS FOR NEW PHARMACEUTICALS – DO THEY HAVE AN IMPACT ON PHARMACEUTICAL REIMBURSEMENT DECISIONS?: A CROSS-NATIONAL COMPARISON

 

Hiller JE, Mundy L
University of Adelaide, Adelaide, South Australia, Australia

   

HT2

COST-EFFECTIVENESS OF INTERVENTIONS FOR REDUCING ROAD TRAFFIC INJURIES RELATED TO DRIVING UNDER THE INFLUENCE OF ALCOHOL

 

Ditsuwan V1, Veerman JL2, Bertram M2, Vos T2
1Thaksin University, Phatthalung, Thailand, 2The University of Queensland, Brisbane, Queensland, Australia

   

HT3

COST-EFFECTIVENESS OF BLOOD PRESSURE LOWERING WITH A FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE IN TYPE 2 DIABETES MELLITUS: A TRIAL-BASED ANALYSIS USING THE ADVANCE STUDY

 

Clarke PM1, Glasziou P2, Alexander J3, Chalmers J4, Patel A5
1University of Sydney, Sydney , NSW, Australia, 2University of Oxford, Oxford, Oxfordshire, United Kingdom, 3University of Queensland, Brisbane, Queensland, Australia, 4George Institute, Sydney, Australia, 5George Institute, Sydney, Australia

   

HT4

HEALTH TECHNOLOGY ASSESSMENT DATABASE IN THAILAND

 

Kapol N, Lochid-amnuay S, Chalongsuk R, Maitreemit P, Sribundit N, Amrumpai Y
Silpakorn University, A.Muang, Nakhon Pathom, Thailand

 
INFECTIOUS DISEASE STUDIES

IN1

ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES AND ACUTE OTITIS MEDIA IN TAIWAN: A NATIONWIDE POPULATION-BASED DATABASE ANALYSIS

 

Chang CJ1, Wang PC2, Huang YC3, Wu BS4
1Chang Gung University, Taoyuan, Taiwan, 2Cathay General Hospital, Taipei, Taiwan, 3Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4National Yang-Ming University, Taipei, Taiwan

   

IN2

COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR TUBERCULOSIS CONTROL PROGRAMMES IN THAILAND

 

Hunchangsith P, Barendregt JJ, Vos T, Bertram M
The University of Queensland, Brisbane, Queensland, Australia

   

IN3

ASSESSMENT OF KNOWLEDGE ABOUT TUBERCULOSIS AMONG LIBYAN POPULATION IN NORTH EAST LIBYA

 

Solliman MM1, Hassali MA2, Al-Haddad M1, Hadidan MM3
1Universiti Sains Malaysia, P.Penang, Malaysia, 2Universiti Sains Malaysia, Minden, Penang, Malaysia, 3Alfatih Medical Sciences University, Tripoli, Libya

   

IN4

HERPES ZOSTER-ASSOCIATED ILLNESSES, QUALITY OF LIFE AND HEALTHCARE COSTS AMONG 180 THAI PATIENTS

 

Aunhachoke K1, Bussaratid V2, Chirachanakul P3, Chua-Intra B3, Dhitavat J2, Jaisathaporn K4, Kaewkungwal J2, Kampirapap K4, Khuhaprema T4, Pairayayutakul K3, Pitisuttithum P2, Sindhvananda J4, Thaipisuttikul Y5
1Phramongkutklao Hospital, Bangkok, Bangkok, Thailand, 2Mahidol University, Bangkok, Thailand, 3Ministry of Public Health, Nonthaburi, Thailand, 4Ministry of Public Health, Bangkok, Thailand, 5Rajvithi Hospital, Bangkok, Thailand

 

RESEARCH ON METHODS

ME1

METHODOLOGICAL ISSUES IN THE DEVELOPMENT OF AN AUSTRALIAN ALGORITHM FOR THE EQ-5D

 

Viney R1, Norman R1, King M2, Street DJ1, Knox S1, Cronin P1
1University of Technology, Sydney, Broadway, NSW, Australia, 2University of Sydney, Sydney, NSW, Australia

   

ME2

VALIDATING THE ACCURACY OF A NOVEL METHOD FOR IDENTIFYING HEALTHCARE-ASSOCIATED INFECTIONS

 

Lee J, Imanaka Y, Sekimoto M, Nishikawa H, Ikai H, Motohashi T
Kyoto University, Kyoto, Japan

   

ME3

COST METHOD: A SIMPLE FRAMEWORK AND WORKING TOOL FOR BUDGET IMPACT ANALYSIS

 

Lo PC1, Shau WY1, Tarn YH2, Chern HD1
1Center for Drug Evaluation, Taipei, Taiwan, 2Taiwan Pharmacist Association, Taipei, Taiwan

   

ME4

DEVELOPMENT OF STANDARD COST LIST FOR ECONOMIC EVALUATION IN THAILAND

 

Riewpaiboon A1, Koopitakkajorn T1, Kumluang S1, Chaikledkaew U1, Khiaocharoen O2
1Mahidol University Faculty of Pharmacy, Bangkok, Thailand, 2Naresuan University Faculty of Medicine, Pitsanuloke, Thailand

6:00PM 7:00PM
RESEARCH PODIUM PRESENTATIONS SESSION II

CARDIOVASCULAR STUDIES

CV1

USING REAL WORLD DATA TO CALCULATE THE COST-EFFECTIVENESS OF STATIN AMONG PARTICIPANTS WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIAN GENERAL PRACTICE

 

Ademi Z1, Liew D2, Hollingsworth B1, Steg PG3, Bhatt D4, Reid C1
1Monash University, Melbourne, Australia, 2The University of Melbourne, Fitzroy, Victoria, Australia, 3Université Paris VII - Denis Diderot, Paris, France, 4Harvard Medical School, Boston , MA, USA

   

CV2

ATTRIBUTABLE COST AND LENGTH OF STAY FOR PATIENTS WITH ENOXAPARIN-ASSOCIATED BLEEDING

 

Khaisombat N1, Saokaew S2, Chaiyakunapruk N3, Nathisuwan S1
1Mahidol University, Bangkok, Thailand, 2Naresuan University Phayao, Muang, Phayao, Thailand, 3Center of Pharmaceutical Outcome Research, Naresuan University, Muang, Phitsanulok, Thailand

   

CV3

COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA

 

Chen XB1, Wang CY2, Eggington S3, Zhu M4
1School of Public Health, Fudan University, Shanghai, China, 2IMS China, Beijing, China, 3IMS Health, London, UK, 4Bayer Healthcare Company Ltd., Beijing, China

   

CV4

THE CLINICAL EFFECTIVENESS OF 64-SLICE OR HIGHER COMPUTED TOMOGRAPHY ANGIOGRAPHY AS AN ALTERNATIVE TO INVASIVE CORONARY ANGIOGRAPHY IN THE INVESTIGATION OF SUSPECTED CORONARY ARTERY DISEASE

 

Paech D, Weston A
Health Technology Analysts Pty Ltd, Sydney, NSW, Australia

 

DIABETES STUDIES

DB1

EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELLING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

 

Chang J1, Sun F1, Li H2
1Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 2China Pharmaceutical University, Nanjing, Jiangsu, China

   

DB2

TRANSLATION AND VALIDATION OF MICHIGAN DIABETES KNOWLEDGE SCALE INTO MALAYSIAN VERSION

 

Al-Qazaz HK1, Hassali MA1, Shafie AA1, Sulaiman SA1, Sundram S2
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2Hospital Balik Pulau, Balik Pulau, P.Penang, Malaysia

   

DB3

COST-UTILITY ANAYLSIS OF INTENSIVE LIFESTYLE INTERVENTIONS OR METFORMIN VERSUS STANDARD CARE IN THE PREVENTION OF TYPE 2 DIABETES IN HIGH RISK SUBJECTS IN AN AUSTRALIAN SETTING. A SIMULATION ANALYSIS BASED ON THE LONG TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND DIABETES PREVENTION PROGRAM OUTCOMES STUDY

 

Tucker DM, Palmer AJ
Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia

   

DB4

ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM

 

Hsiao FY1, Mullins CD1, Huang WF2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan

 

DATABASE STUDIES

DS1

ESTIMATING ADHERENCE AND PERSISTENCY OF ANTIDEPRESSANTS USING THE KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

 

Jung SY, Song H, Shin S, Shin E, Park J, Ahn J
National Evidence-based healthcare Collaborating Agency, Seoul, South Korea

   

DS2

TREND OF ANTI-HYPERTENSIVE MEDICATIONS AND RISK OF STROKE AMONG HYPERTENSIVE PATIENTS IN TAIWAN: BASED ON THE NHI DATABASE

 

Chu NF
Shuang-Ho Hispital, TMU, School of Public Health, NDMC, Taipei, Taiwan, Taiwan

   

DS3

A COMPARISON OF SIGNAL DETECTION PERFORMANCE BETWEEN REPORTING ODDS RATIO AND BAYESIAN CONFIDENCE PROPAGATION NEURAL NETWORK METHODS ON ADVERSE DRUG REACTION SPONTANEOUS REPORTING DATABASE OF THE THAI FDA

 

Bunchuailua W1, Zuckerman I2, Kulsomboon V3, Suwankesawong W4, Singhasivanon P5, Kaewkungwal J5
1Faculty of Pharmacy Silpakorn University, Muang, Nakhon Pathom, Thailand, 2University of Maryland, Baltimore, Baltimore, MD, USA, 3Chulalongkorn University, Bangkok, Thailand, 4Food and Drug Administration, Muang, Nonthaburi, Thailand, 5Faculty of Tropical Medicine Mahidol University, Ratchawithi, Bangkok, Thailand

   

DS4

HERBAL PRODUCTS SAFETY: AN APPLICATION OF HEALTH PRODUCT VIGILANCE CENTER DATABASE

 

Saokaew S1, Suwankesawong W2, Permsuwan U3, Chaiyakunapruk N4
1Naresuan Univeristy Phayao, Muang, Phayao, Thailand, 2Ministry of Public Health,  Nonthaburi, Thailand, 3Chiang Mai University, Muang, Chiang Mai, Thailand, 4Center of Pharmaceutical Outcomes Research (CPOR), Phitsanulok, Thailand

 

DRUG USE STUDIES

DU1

THE IMPACTS OF ABUSE OF ANTIBIOTIC THERAPIES IN CHINA

 

Yang L
Peking university, Beijing, Beijing, China

   

DU2

THE UTILIZATION OF PROPHYLACTIC ANTITHROMBOTIC AGENTS AFTER MAJOR ORTHOPEDIC SURGERIES- A POPULATION-BASED STUDY IN TAIWAN

 

Yu YY1, Chen LC1, Cheng LJ2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2University of Macau, Macau, Macau

   

DU3

ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS OF THE MALAYSIAN COMMUNITY PHARMACISTS REGARDING PHARMACOVIGILANCE: FINDINGS FROM AN INTERVENTIONAL STUDY

 

Elkalmi RM1, Hassali MA1, Izham M2
1Universiti Sains Malaysia, Minden, Penang, Malaysia, 2University Sains Malaysia, Minden, Penang, Malaysia

   

DU4

COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE (T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN MALAYSIA AND INDIA

 

Taylor M1, Tan R2
1York Health Economics Consortium, York, UK, 2Alcon Laboratories R&D International, Singapore, Singapore

 

HEALTH EXPENDITURE STUDIES

HE1

A CROSS-COUNTRY COMPRASION OF HEALTH PERFORMANCE BETWEEN TAX-FUNDED AND SOCIAL HEALTH INSURANCE SYSTEM: THE CHANNEL VIA PREVENTIVE CARE

 

Chen Q, Li L
Peking University, Beijing, China

   

HE2

NEW DRUGS AND THE GROWTH OF HEALTH EXPENDITURE: EVIDENCE FROM DIABETIC PATIENTS IN TAIWAN

 

Liu YM1, Hsieh CR2
1National Cheng Kung University, Tainan, Taiwan, 2Academia Sinica, Taipei, Taiwan

   

HE3

ANALYSIS OF AN AFFORDABLE PRICE FOR PERFORMANCE-BASED RISK SHARING SCHEME: OMALIZUMAB ADAPTATION IN KOREA

 

Kim S, Kim J, Kim J, Kim C, Shin K, Kim K, Kim H
Novartis Korea, Seoul, South Korea

   

HE4

THE EFFECT OF PRICE CONTAINMENT ON THE TREND OF PHARMACEUTICAL EXPENDITURE FROM 1999 TO 2007 IN TAIWAN

 

Lang HC1, Tan CH2
1National Yang-Ming University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan

7:00PM 8:00PM
POSTER AUTHOR DISCUSSION HOUR
7:00PM 9:00PM
RECEPTION, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING
7:00PM 9:00PM
ISPOR ASIA CONSORTIUM MEETING (BY INVITATION)
Executive Committee Business Meeting
9:15PM 10:30PM
ISPOR ASIA CONSORTIUM MEETING (BY INVITATION)
ISPOR 5th Asia-Pacific Conference Program Committee Business Meeting
  Sunday, 5 September >> Monday, 6 September >> Tuesday, 7 September

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.